Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 13/20 | 0.81 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | KLK7 | P49862 | 1/20 | 0.66 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31488020 | 1.00 | PARP14 (0.81) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL29371973 | 0.90 | PARP14 (1.00) | PARP14 | |
| SCHEMBL3077145 | 0.85 | JAK2 (0.68) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL9418204 | 0.83 | JAK2 (0.66) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL10961185 | 0.83 | JAK2 (0.70) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL10966763 | 0.83 | JAK2 (0.66) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL20887144 | 0.83 | TP53 (0.61) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL20887145 | 0.83 | PARP14 (0.82) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL20887147 | 0.81 | PARP14 (0.82) | PARP14JAK2TP53MAPTHTT | |
| SCHEMBL3072103 | 0.78 | PARP14 (0.60) | PARP14JAK2TP53MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119463156-A | Amphiphilic organic near-infrared thermal activation delayed fluorescence molecule and preparation method and application thereof | 内蒙古大学 | 2025-02-18 | — | — | CN | disclosed |
| WO-2019071104-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HYPERAMMONEMIA | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2019-04-11 | — | — | WO | disclosed |
| US-7491245-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080098535-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof | GLENN ROBERT W JR | 2008-05-01 | — | — | US | disclosed |
| US-7331997-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| CN-1937994-A | Keratin dyeing compounds, keratin dyeing compositions containing them and their use | PROCTER & GAMBLE (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1735059-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005099656-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050217038-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050217038-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, TUBB6 | PARP14 2647/4885JAK2 4614/4885TP53 499/4885 |
| US-20080098535-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof | KRT18, CKMT1A; CKMT1B, TUBB6 | PARP14 2647/4885JAK2 4614/4885TP53 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.